Chemotherapy in malignant pleural mesothelioma: A review

Journal of Clinical Oncology

Volumn 14, Issue 3, 1996, Pages 1007-1017

  Ong, S T ^a   Vogelzang, N J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10 PROPARGYL 5,8 DIDEAZAFOLIC ACID; ALKYLATING AGENT; ALPHA2A INTERFERON; ANTHRACYCLINE ANTIBIOTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DETORUBICIN; DOXORUBICIN; EDATREXATE; EPIRUBICIN; FLUOROURACIL; FOLIC ACID ANTAGONIST; GAMMA INTERFERON; IFOSFAMIDE; INTERLEUKIN 2; MITOMYCIN; MITOXANTRONE; PACLITAXEL; PIRARUBICIN; PLATINUM DERIVATIVE; SURAMIN; TRIMETREXATE; VINCA ALKALOID; VINDESINE;

CLINICAL PROTOCOL; DRUG EFFICACY; DRUG RESPONSE; HUMAN; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0029928641     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.3.1007     Document Type: Review

References (79)

1. Connelly RR, Spirtas R, Myers MH, et al: Demographic patterns for mesothelioma in the United States. J Natl Cancer Inst 78:1053-1060, 1987
2. Driscoll TA, Baker GJ, Daniels S, et al: Clinical aspects of malignant mesothelioma in Australia. Aust NZ J Med 23:19-25, 1993 (suppl 1)
3. Sridhar KS, Doria R, Raub WA, et al: New strategies are needed in diffuse malignant mesothelioma. Cancer 70:2969-2979, 1992
4. Sugarbaker DJ, Strauss GM, Lynch TJ, et al: Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol 11:1172-1178, 1993
5. Antman KH, Li FP, Pass HI, et al: Benign and malignant mesothelioma, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 4). Philadelphia, PA, Lippincott, 1993, pp 1489-1508
6. Aisner J, Sigman LM: The role of chemotherapy in the treatment of malignant mesothelioma, in Antman K, Aisner J (eds): Asbestos-Related Malignancy. Orlando, FL, Grune & Stratton, 1986, pp 385-401
7. Lerner HJ, Schoenfeld DA, Martin A, et al: Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer 52:1981-1985, 1983
8. Sorensen PH, Bach F, Bork E, et al: Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep 69:1431-1432, 1985
9. Harvey VJ, Slevin ML, Ponder BAJ, et al: Chemotherapy of diffuse malignant mesothelioma: Phase 11 trials of single agent 5-fluorouracil and Adriamycin. Cancer 54:961-964, 1984
10. Gertler SZ, Stewart DJ, Tomiak A, et al: High dose doxorubicin plus cisplatin for unresectable mesotheliomas: Report of four cases. Proc Am Soc Clin Oncol 13:346, 1994 (abstr 1156)
11. Colbert N, Vannetzel JM, Izrael V, et al: A prospective study of detorubicin in malignant mesothelioma. Cancer 56:2170-2174, 1985
12. Kaukel E, Koschel G, Gatzemeyer U, et al: A phase II study of pirarubicin in malignant pleural mesothelioma. Cancer 66:651-654, 1990
13. Sridhar KS, Hussein AM, Feun LG, et al: Activity of pirarubicin (4′tetrahydropyranyladriamuycin) in malignant mesothelioma. Cancer 63:1084-1091, 1989
14. Koschel G, Calavrezos A, Kaukel E, et al: Phase III randomized comparison of pirarubicin vs. pirarubicin and cisplatin for treatment of pleural mesotheliomas. Proceedings of the Sixth European Congress Against Cancer, 1991
15. Magri MD, Veronesi A, Foladore S, et al: Epirubicin in the treatment of malignant mesothelioma: A phase II cooperative study. Tumori 77:49-51, 1991
16. Mattson K, Giaccone G, Kirkparick A, et al: Epirubicin in malignant mesothelioma: A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 10:824-828, 1992
17. Eisenhauer EA, Evans WK, Raghavan D, et al: Phase II study of mitoxantrone in patients with mesothelioma: A National Cancer Institute of Canada Clinical Trials Group study. Cancer Treat Rep 70:1029-1030, 1986
18. Van Breukelen FJM, Mattson K, Giaccone G, et al: Mitoxantrone in malignant pleural mesothelioma: A study by the EORTC Lung Cancer Cooperative Group. Eur J Cancer 27:1629-1633, 1991
19. Mintzer DM, Kelsen D, Frimmer D, et al: Phase II trial of high dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep 69:711-712, 1985
20. Zidar BL, Green S, Pierce HI, et al: A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group Study. Invest New Drugs 6:223-226, 1988
21. Planting A, Goey H, Verweij J: Phase II study of six weekly courses of high dose cisplatin (CDDP) in mesothelioma. Proc Am Assoc Cancer Res 32:194, 1991 (abstr 1158)
22. Mbidde EK, Harland SJ, Cavert AH, et al: Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma. Cancer Chemother Pharmacol 18:284-285, 1986
23. Mbidde EK, Smith IE, Harland SJ: Phase II trial of carboplatin (JM8) in the treatment of patients with mesothelioma (M). Br J Cancer 54:215-216, 1986
24. Raghavan D, Gianoutsos P, Bishop J, et al: Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 8:151-154, 1990
25. Vogelzang NJ, Goutsou M, Corson JM, et al: Carboplatin in malignant mesothelioma: A phase II study of the Cancer and Leukemia Group B. Cancer Chemother Pharmacol 27:239-242, 1990
26. Kelsen D, Gralla R, Cheng E, et al: Vindesine in the treatment of malignant mesothelioma: A phase II study. Cancer Treat Rep 67:821-822, 1983
27. Boutin C, Irisson M, Guerin JC, et al: Phase II trial of vindesine in malignant pleural mesothelioma. Cancer Treat Rep 71:205-206, 1987
28. Martensson G, Sorenson S: A phase II study of vincristine in malignant mesothelioma - A negative report. Cancer Chemother Pharmacol 24:133-134, 1989
29. Cowan JD, Green S, Lucas J, et al: Phase II trial of five day intravenous infusion vinblastine sulfate in patients with diffuse malignant mesothelioma: A Southwest Oncology Group study. Invest New Drugs 6:247-248, 1988 (letter)
30. Vogelzang NJ, Herndon J, Clamon GH, et al: Paclitaxel (Taxol) for malignant mesothelioma (MM): A phase II study of the Cancer and Leukemia Group B (CALGB 9234). Proc Am Soc Clin Oncol 13:405, 1994 (abstr 1382)
31. Murphy WK, Fossella FV, Winn RJ, et al: Phase II study of Taxol in patients with untreated non-small cell lung cancer. J Natl Cancer Inst 85:384-388, 1993
32. Current Clinical Trials: Oncology National Cancer Institute/ PDQ, vol 1, no. 2. Green Brook, NJ, Pyros Education Group, Mar/ Apr 1994
33. Alberts AS, Falkson G, Zyl LV: Malignant pleural mesothelioma: Phase II pilot study of ifosfamide and mesna. J Natl Cancer Inst 80:668-700, 1988
34. Zidar BL, Metch B, Balcerzak SP, et al: A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group study. Cancer 70:2547-2551, 1992
35. Falkson G, Hunt M, Borden EC, et al: An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. Invest New Drugs 10:337-343, 1992
36. Bajorin D, Kelsen D, Mintzer DM: Phase II trial of mitomycin in malignant mesothelioma. Cancer Treat Rep 71:857-858, 1987
37. Solheim OP, Saeter G, Finnanger AM, et al: High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 65:956-960, 1992
38. Dmitrov NV, Egner J, Balcueva E, et al: High-dose methotrexate with citrovorum factor and vincristine in the treatment of malignant mesothelioma. Cancer 50:1245-1247, 1982
39. Djerassi I, Kim JS, Kassarov L, et al: Response of mesothelioma to large doses of methotrexate CF with rescue (HDMTXCF) used alone or with cis platinum. Proc Am Soc Clin Oncol 4:191, 1985 (abstr C-745)
40. Vogelzang NJ, Weissman LB, Herndon JE, et al: Trimetrexate in malignant mesothelioma: A CALGB phase II study. J Clin Oncol 12:1436-1442, 1994
41. Belani CP, Herndon J, Vogelzang NJ, et al: Edatrexate for malignant mesothelioma: A phase II study of the Cancer and Leukemia Group B, 9131. Proc Am Soc Clin Oncol 13:329, 1994 (abstr 1087)
42. Belani LP, Herndon J, Vogelzang NJ, et al: Edatrexate with oral leucovorin rescue for malignant mesothelioma: A phase II study of the Cancer and Leukemia Group B - CALGB 9131. Proc Am Soc Clin Oncol 14:352, 1995 (abstr 1068)
43. N10-propargyl-5,8 dideazafolic acid (CB3717), in malignant mesothelioma. Cancer Treat Rep 70:1335-1336, 1986
44. Harmon D, Vogelzang NJ, Roboz J, et al: Dihydro-5-azacytidine (DHAC) in malignant mesothelioma (Meso) using serum hyaluronic acid (SHA) as a tumor marker: A phase II trial of the CALGB. Proc Am Soc Clin Oncol 10:351, 1991 (abstr 1248)
45. Dhingra HM, Murphy WK, Winn RJ, et al: Phase II trial of 5,6-dihydro-5-azacytidine in pleural malignant mesothelioma. Invest New Drugs 9:69-71, 1991
46. Samuels BL, Herndon J, Vogelzang NJ, et al: Dihydro-5-azacytidine (DHAC) and cisplatin (DDP) in mesothelioma (CALGB 9031). Proc Am Soc Clin Oncol 13:402, 1994 (abstr 1371)
47. Falkson G, Vorobiof DA, Lerner JH, et al: A phase II study of M-AMSA in patients with malignant mesothelioma. Cancer Chemother Pharmacol 4:135, 1980
48. Eagan R, Frytak S, Richardson R, et al: Phase II trial of diaziquone in malignant mesothelioma. Cancer Treat Rep 70:429, 1986
49. Webster I, Cochrane JWC, Burkhardt KR, et al: Immunotherapy with BCG vaccine in 30 cases of mesothelioma. S Afr Med J 61:277, 1982
50. Alberts AS, Falkson G, Goedhals L, et al: Malignant pleural mesothelioma: A disease unaffected by current therapeutic maneuvers. J Clin Oncol 6:527-535, 1988
51. Christmas TI, Manning LS, Garlepp MJ, et al: Effect of interferon-alpha 2a on malignant mesothelioma. J Interferon Res 13:9-12, 1993
52. Upham JW, Musk AW, van-Hagel G, et al: Interferon alpha and doxorubicin in malignant mesothelioma: A phase II study. Aust NZ J Med 2316:683-687, 1993
53. Pogrebniak H, Kranda K, Steinberg S, et al: Cisplatin, interferon-α, and tamoxifen (CIT) for malignant pleural mesothelioma. Proc Am Soc Clin Oncol 12:398, 1993 (abstr 1363)
54. Tansan S, Emri S, Selcuk T, et al: Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon. Oncology 51:348-351, 1994
55. Trandafir L, Borel C, Ruffie P, et al: Combined systemic CDDP-interferon α (IFN) in advanced pleural malignant mesothelioma (MM). Proc Am Soc Clin Oncol 13:405, 1994 (abstr 1384)
56. Von Hoff DD, Metch B, Lucas JG, et al: Phase II evaluation of recombinant interferon-beta (FN-beta ser) in patients with diffuse mesothelioma: A Southwest Oncology Group study. J Interferon Res 10:531-534, 1990
57. Samson M, Wasser L, Borden EC, et al: Randomized comparison of cyclophosphamide, DTIC and Adriamycin vs. cyclophosphamide and Adriamycin in patients with advanced stage malignant mesothelioma: A Sarcoma Intergroup study. J Clin Oncol 5:86-91, 1987
58. Dhingra H, Valdivieso M, Tannir N, et al: Combined modality treatment for mesothelioma with Cytoxan, Adriamycin, and DTIC (CYADIC) and adjuvant surgery. Proc Am Soc Clin Oncol 2:205:1983 (abstr C-800)
59. Carmichael J, Cantwell BM, Harris AL, et al: A phase II trial of ifosfamide/mensa with doxorubicin for malignant mesothelioma. Eur J Cancer Clin Oncol 25:911-912, 1989
60. Alberts AS, Falkson G, van Zyl L, et al: Ifosfamide and mensa with doxorubicin have activity in malignant mesothelioma. Eur J Cancer 26:1002, 1990
61. Shin DM, Fossella FB, Putnam JB, et al: Phase II study of combination chemotherapy with Cytoxan (C), Adriamycin (A), and cisplatin (P) for unresectable or metastatic malignant pleural mesothelioma (MPM). Proc Am Soc Clin Oncol 12:398 1993 (abstr 1362)
62. Ardizzoni A, Rosso R, Salvati F, et al: Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) phase II study. Cancer 67:2984-2987, 1991
63. Chahinian AP, Antman K, Goutsou M, et al; Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 11:1559-1565, 1993
64. Magri MD, Foladore S, Veronis A, et al: Treatment of malignant mesothelioma with epirubicin and ifosfamide; A phase II comparative study. Ann Oncol 3:237-238, 1992
65. Zidar BL, Benjamin RS, Frank J, et al: Combination chemotherapy for advanced sarcomas of bone and mesothelioma utilizing rubidazone and DTIC: A Southwest Oncology Group study. Am J Clin Oncol 6:71-74, 1983
66. Chahinian AP, Pajak TF, Holland JF, et al: Diffuse malignant mesothelioma: Prospective evaluation of 69 patients. Ann Intern Med 96:746-755, 1982 (suppl 1)
67. Breau JL, Boaziz C, Morere JJF, et al: Combination chemotherapy with cisplatinum, Adriamycin, bleomycin and mitomycin C, plus systemic and intra-pleural hyaluronidase in 25 consecutive cases of stages II, III pleural mesothelioma. Presented at the First International Mesothelioma Conference, Paris, France, 1991:5
68. Eisenhauer EA, Evans WK, Murray N, et al: A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma. An NCI Canada Clinical Trials Group study. Invest New Drugs 6:327-329, 1988
69. Markman M, Howell S, Green MR, et al: Combination intra-cavitary chemotherapy for malignant pleural disease. Cancer Drug Deliv 1:333-336, 1984
70. Markman M, Cleary S, King M, et al: Cisplatin and cytarabine administered intra-pleurally as treatment of malignant pleural effusions. Med Pediatr Oncol 13:191-193, 1985
71. Markman M, Cleary S, Pfeifle C, et al: Cisplatin administered by the intra-cavitary route as treatment for malignant mesothelioma. Cancer 58:18-21, 1986
72. Rusch V, Figlin R, Godwin D, et al: Intra-pleural cisplatin and cytarabine in the management of malignant pleural effusions: A Lung Cancer Study Group trial. J Clin Oncol 9:313-319, 1991
73. Rusch V, Niedzwiecki D, Tao Y, et al: Intra-pleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: Pharmacokinetic studies. J Clin Oncol 10:1001-1006, 1992
74. Aitini E, Pasquini E, Cavazzini G, et al: Local treatment of malignant pleural mesothelioma with intra-cavitary cytosine-arabinoside and cisplatin. Ann Oncol 3:771-774, 1992
75. Eggermont AMM, Goey SH, Slingerland R, et al: Clinical and immunological evaluation of intrapleural (IPL) interleukin-2 (1L-2) in malignant pleural mesothelioma: A phase I-II study. Proc Am Assoc Cancer Res 32:206, 1991 (abstr)
76. Boutin C, Viallat JR, Van-Zandwijk N, et al: Activity of intra-pleural recombinant gamma-interferon in malignant mesothelioma. Cancer 67:2033-2037, 1991
77. Sklarin NT, Chahinian AP, Fever E, et al: Augmentation of activity of cisplatin and mitomycin C by interferon in human malignant mesothelioma xenografts in nude mice. Cancer Res 48:64-67, 1988
78. Licht T, Fiebeg HH, Bross KJ, et al: Induction of multiple-drug resistance during anti-neoplastic chemotherapy in vitro. Int J Cancer 49:630-637, 1991
79. Aisner J, Arriagada R, Green MR, et al (eds): Comprehensive Textbook of Thoracic Oncology. Baltimore, MD, Williams & Wilkins, 1996 (in press)